Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

Basit Öğe Kaydı
dc.authoridYildirim, Hasan cagri/0000-0003-3060-377X
dc.authorscopusid57218372808
dc.authorscopusid57916069400
dc.authorscopusid57912056900
dc.authorscopusid57705985300
dc.authorscopusid57801244000
dc.authorscopusid57796929000
dc.authorscopusid57366332800
dc.contributor.authorYildirim, Hasan Cagri
dc.contributor.authorMutlu, Emel
dc.contributor.authorChalabiyev, Elvin
dc.contributor.authorOzen, Mirac
dc.contributor.authorKeskinkilic, Merve
dc.contributor.authorOn, Sercan
dc.contributor.authorCelebi, Abdussamet
dc.date.accessioned2023-01-12T19:54:30Z
dc.date.available2023-01-12T19:54:30Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractBackground: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer. Therefore; we aimed to investigate the treatment responses of metastatic HR+, HER2-male breast cancer patients treated with CDK 4-6 inhibitors in a multicenter real-life cohort. Methods: Male patients with a diagnosis of HR+ and HER2-metastatic breast cancer, treated with any CDK 4-6 inhibitor, were included in the study. Demographic and clinical characteristics of the patients were recorded. We aimed to determine progression-free survival (PFS) time, response rates and drug related side effects. Results: A total 25 patients from 14 institutions were recruited. The mean age at diagnosis was 57 years. Median follow-up was 19.53 (95% CI: 14.04-25.02) months. The overall response rate was 60%. While the median PFS was 20.6 months in the whole cohort, it wasn't reached in those using CDK 4-6 inhibitors in first line and 10 months in the subsequent lines (p:0.009). No new adverse events were encountered. Conclusion: In our study, we found that CDK 4-6 inhibitors are effective and safe options in men with HR+ and HER2-metastatic breast cancer as in women. Our results support the use of CDK 4-6 inhibitor-based combinations in the first-line treatment of HR+ and HER2-metastatic male breast cancer.en_US
dc.identifier.doi10.1016/j.breast.2022.09.009
dc.identifier.endpage88en_US
dc.identifier.issn0960-9776
dc.identifier.issn1532-3080
dc.identifier.pmid36208540en_US
dc.identifier.scopus2-s2.0-85139314359en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage85en_US
dc.identifier.urihttps://doi.org/10.1016/j.breast.2022.09.009
dc.identifier.urihttps://hdl.handle.net/11454/76442
dc.identifier.volume66en_US
dc.identifier.wosWOS:000875350600003en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherChurchill Livingstoneen_US
dc.relation.ispartofBreasten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMale breast canceren_US
dc.subjectPalbocicliben_US
dc.subjectRibocicliben_US
dc.subjectPd 0332991en_US
dc.subjectPhase-Ien_US
dc.subjectFulvestranten_US
dc.subjectAbemacicliben_US
dc.subjectScheduleen_US
dc.titleClinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu